News

The China NMPA's CDE has granted breakthrough therapy designation approval to Abbisko Therapeutics’ irpagratinib for HCC.
About Irpagratinib (ABSK-011) Irpagratinib is a highly-selective FGFR4 small molecule inhibitor designed to target overexpression of the FGF19 signaling pathway. Several epidemiological studies ...
China NMPA grants breakthrough therapy designation to Abbisko Therapeutics’ irpagratinib to treat hepatocellular carcinoma: Shanghai Tuesday, May 27, 2025, 10:00 Hrs [IST] Abbis ...
Irpagratinib is a highly-selective FGFR4 small molecule inhibitor designed to target overexpression of the FGF19 signaling pathway. Several epidemiological studies indicate that approximately 30% of ...
Irpagratinib is a highly-selective FGFR4 small molecule inhibitor designed to target overexpression of the FGF19 signaling pathway. Several epidemiological studies indicate that approximately 30% ...
To date, no FGFR4 inhibitor has been granted regulatory approval globally. According to Frost & Sullivan, irpagratinib is expected to become the first breakthrough treatment for the treatment of HCC ...